NNV024, a novel humanized anti-CD37 antibody with enhanced ADCC and prolonged plasma half-life in human FcRn transgenic mice for treatment of NHL
R. Generaloc, E. Fiorito, S. Foss, V. Pascal, H. Heyerdahl, A. Repetto, J. T. Andersen, G. Tjonnfjord, S. S. Skanland, J. Dahle
This paper develops NNV024, a humanized anti-CD37 antibody with enhanced ADCC and prolonged plasma half-life, showing improved efficacy against NHL and CLL cells compared to existing therapies.
bioRxiv · Jul 12, 2023 · PreprintCancer Biology